[Glycolipid] alpha-Galactosylceramide; α-Galactosylceramide; α-Gal-Cer [KRN7000][CAS no. 158021-47-7]_Funakoshi - 코아사이언스

KRN7000 / α-Galactosylceramide / α-Gal-Cer

Cat.#: KRN7000 / Size : 1 mg

 

 

Chemical name: (2S,3S,4R)-1-O-(α-D-Galactosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol

 

KRN7000, a chemically synthesized α -Galactosylceramide and the marine natural product agelasphin, is a specific ligand for human and mouse natural killer T (NKT) cells, and remains the best studied ligand of the lipid-binding MHC class I-like protein CD1d. 

 

KRN7000 exhibits potent antitumor activity in various kinds of in vivo murine experimental models including subcutaneously implanted model and metastatic models in the liver and lung. In the liver metastatic models, treatment with KRN700 suppressed the growth of tumors and prolonged the survival term of tumor-bearing mice.

 

KRN7000 has been reported to show various immunological effects in infectious disease, autoimmune disease, and graft verse host disease in mice. It protects against LPS-induced shock and displays potent antitumor activity in various in vivo models.

 

 

Specification

Molecular formula:	C50H99NO9
Molecular weight:	858.3
Purity:	≥95%
Appearance:	White to off-white powder
Solubility:	α-Galactosylceramide is practically insoluble in water, methanol or ethanol, very slightly soluble in tetrahydrofuran, slightly soluble in pyridine, and practically insoluble in other organic solvents. (1) In vivo assay：To dissolve KRN7000, use 5.6% sucrose, 0.75% L-histidine and 0.5% Tween20 with heating at around 80°C for several minutes. (2) In vitro assay：KRN7000 should be dissolved by DMSO at the concentration of 1mg/ml with heating at 60-80°C for tens of seconds. The solution of 1mg/ml in DMSO can be diluted by PBS.
Shipping	Shipped on Blue ice
Long Term Storage:	-20°C

 

References

Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments: M. Moll, et al.; Blood in press, (2010), Abstract

 

Invariant valpha14 natural killer T cell activation by edible mushroom acidic glycosphingolipids: H. Nozaki, et al.; Biol. Pharm. Bull. 33, 580 (2010), Abstract

 

Alpha-galactosylceramide-driven immunotherapy for allergy; Ishii Y., et al.; Front Biosci. 13:6214-28 (2008)

 

Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses: Kamijuku H. et al.; Mucosal Immunol. 1(3):208-218 (2008)

 

Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock: G. Sireci, et al.; J. Leukoc. Biol. 81, 607 (2007), Abstract

 

Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d: K.O. Yu, et al.; J. Immunol. Methods 323, 11 (2007), Abstract

 

A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer: A. Ishikawa, et al.; Clin. Cancer Res. 11, 1910 (2005), Abstract

 

Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides: K.O. Yu, et al.; PNAS 102, 3383 (2005), Abstract

 

*본 상품은 오로지 연구 목적으로만 사용할 수 있습니다. 어떠한 제품 개발이나 인체 사용 용도로는 사용하실 수 없습니다. 

 

관련 상품 

7DW8-5 (Derivative of α-Gal-Cer) 

GT1b-Ganglioside [OG03923] [CAS no. 59247-13-1]

[당 잔기 구조 분석] PNGase F PRIME™ Glycosidase [NZS1, NZS1-LY]

coresciences 코아사이언스 Funakoshi co., ltd. 후나코시 한국 공식대리점 일본 후나코시